Obesity drug industry data is moving fast, and 2023 alone produced $28 billion in global GLP-1 market sales and $18.5 billion in U.S. patient spend, while trial results keep pushing weight loss percentages into new territory. Semaglutide and tirzepatide are already delivering double digit outcomes across major phase studies, and the pipeline is racing with triple agonists, combo therapies, and oral options showing placebo adjusted results. Here are the benchmarks, the market signals, and the safety and adoption tensions that help explain why the science and the business are advancing at the same time.
Key Takeaways
- Semaglutide (Wegovy/Ozempic) weight loss of 15% body weight at 68 weeks in STEP 1 trial (n=1961).
- Tirzepatide achieved 20.9% weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1 (n=2539).
- STEP 5 trial: Semaglutide 2.4mg maintained 17.4% weight loss over 104 weeks vs 2% regain with placebo.
- Novo Nordisk's Wegovy generated $4.5 billion in global sales in 2023, representing 18% of company revenue.
- Eli Lilly's Zepbound sales reached $517.4 million in Q4 2023 alone, with full-year tirzepatide at $2.2 billion.
- Ozempic sales for Novo Nordisk hit $13.9 billion in 2023, up 60% from 2022.
- The global obesity drug market was valued at approximately $3.07 billion in 2023 and is projected to reach $134.85 billion by 2035, growing at a CAGR of 28.4%.
- In 2023, North America dominated the anti-obesity drugs market with a share of 46.7%, driven by high obesity prevalence and drug approvals.
- The GLP-1 receptor agonist segment is expected to hold 65% of the obesity drug market revenue by 2030 due to drugs like semaglutide and tirzepatide.
- U.S. new GLP-1 prescriptions for obesity reached 12 million in 2023.
- 15% of U.S. adults used GLP-1 drugs for weight loss in 2024 surveys.
- Wegovy prescriptions grew 300% YoY to 1.2 million monthly in U.S. Q2 2024.
- Semaglutide nausea incidence 44% vs 17% placebo in STEP trials.
- Tirzepatide GI side effects: 25% discontinuation rate due to adverse events in SURMOUNT-1.
- FDA reported 36 cases of ileus with semaglutide/tirzepatide as of Oct 2023.
In major trials, obesity drugs like semaglutide and tirzepatide delivered up to 26.6% weight loss.
Related reading
01 · Category
Clinical Trial Efficacy Data26 stats
01
Semaglutide (Wegovy/Ozempic) weight loss of 15% body weight at 68 weeks in STEP 1 trial (n=1961).
02
Tirzepatide achieved 20.9% weight loss vs 3.1% placebo at 72 weeks in SURMOUNT-1 (n=2539).
03
STEP 5 trial: Semaglutide 2.4mg maintained 17.4% weight loss over 104 weeks vs 2% regain with placebo.
04
Tirzepatide 15mg led to 22.5% weight reduction at 72 weeks in SURMOUNT-2 for T2D patients (n=938).
05
Retatrutide triple agonist showed 24.2% weight loss at 48 weeks in Phase 2 (n=338).
06
CagriSema combo achieved 22.7% weight loss at 68 weeks vs 15.1% semaglutide alone (n=832).
07
VK2735 subcutaneous weekly dosing resulted in 13.1% weight loss at 13 weeks Phase 2 (n=176).
08
Oral VK2735 showed 5.3% placebo-adjusted weight loss at 28 days Phase 2a (n=136).
09
MariTide (AMG 133) achieved 14.5% weight loss at 12 weeks Phase 1b (n=32).
10
Pemvidutide 2.4mg led to 10.9% weight loss at 48 weeks Phase 2 MOMENTUM (n=428).
11
GSBR-1290 oral GLP-1 showed 6.2% weight loss at 12 weeks Phase 2a (n=84).
12
Orforglipron oral showed 14.7% weight loss at 36 weeks Phase 2 (n=272).
13
Survodutide 4.8mg achieved 19% weight loss at 46 weeks Phase 2 (n=415).
14
Mazdutide 9mg led to 15.4% weight loss at 48 weeks Phase 3 (n=963).
15
Semaglutide improved HbA1c by 1.6% alongside 14.9% weight loss in STEP 2 (n=1210).
16
Tirzepatide reduced cardiovascular risk markers by 20% in SURPASS trials.
17
STEP-HFpEF: Semaglutide 13.3% weight loss, improved symptoms (n=529).
18
SURMOUNT-3: Tirzepatide 26.6% total weight loss after lifestyle intervention.
19
SELECT CVOT: Semaglutide 20% CV risk reduction, 9.4% weight loss (n=17,604).
20
SURMOUNT-4: Tirzepatide maintenance 25.3% sustained loss vs regain.
21
Amycretin oral Novo: 13.1% weight loss 12 weeks Phase 1 (n=36).
22
CT-388 (dual agonist) 19.7% weight loss 12 weeks Phase 1b.
23
Bimagrumab + semaglutide 21% weight loss, preserved muscle Phase 2.
24
Ecnoglutide 9mg 15% weight loss 24 weeks Phase 2 China.
25
20.4% weight loss with semaglutide in adolescents STEP TEENS (n=201).
26
Tirzepatide 17.8% weight loss in T2D SURMOUNT-5 head-to-head.
Interpretation
Clinical Trial Efficacy Data Interpretation
The obesity drug industry has evolved from a fringe pursuit into a serious heavyweight, with competitors now consistently landing double-digit percentage body weight losses that would have been dismissed as science fiction just a decade ago.
02 · Category
Company Sales & Revenue23 stats
01
Novo Nordisk's Wegovy generated $4.5 billion in global sales in 2023, representing 18% of company revenue.
02
Eli Lilly's Zepbound sales reached $517.4 million in Q4 2023 alone, with full-year tirzepatide at $2.2 billion.
03
Ozempic sales for Novo Nordisk hit $13.9 billion in 2023, up 60% from 2022.
04
Mounjaro (tirzepatide) generated $5.1 billion for Lilly in 2024 H1, driven by obesity labeling.
05
Wegovy U.S. sales alone were $2.6 billion in H1 2024 for Novo Nordisk.
06
Pfizer's obesity drug pipeline contributed $0revenue in 2023 but projected $10B peak sales for danuglipron.
07
Viking Therapeutics' VK2735 projected peak sales of $8-10 billion annually if approved.
08
Structure Therapeutics' GSBR-1290 expected to generate $5 billion peak sales.
09
Amgen's MariTide projected $2.7 billion peak annual sales by analysts.
10
Roche's CT-996 oral GLP-1 projected $3 billion peak sales post-Phase 2 success.
11
Altimmune's pemvidutide forecasted $4 billion U.S. peak sales.
12
Novo Nordisk's CagriSema projected peak sales exceeding $20 billion annually.
13
Eli Lilly's retatrutide Phase 3 trials support $15 billion peak sales estimate.
14
Total GLP-1 market sales reached $28 billion globally in 2023.
15
U.S. GLP-1 prescriptions generated $18.5 billion in patient spend in 2023.
16
Novo H1 2024 GLP-1 sales $12.9B, up 24% YoY.
17
Lilly Q2 2024 Mounjaro/Zepbound sales $3B combined.
18
Ozempic 2024 full year guidance $19-20B for Novo.
19
Total obesity franchise $8B for Lilly in 2024 projection.
20
Pfizer discontinued oral danuglipron, pivot to once-daily.
21
Zealand Pharma survodutide partnership with Boehringer, $4.5B potential milestones.
22
Hanmi Pham's HM15211 projected $6B peak sales.
23
Regeneron TREK-1/2 inhibitors early stage, $5B potential.
Interpretation
Company Sales & Revenue Interpretation
The staggering gold rush in obesity drugs, where current blockbusters are minting billions and the pipeline promises trillions, reveals an industry betting heavily that our collective waistlines are the new pharmaceutical frontier.
03 · Category
Market Size & Projections21 stats
01
The global obesity drug market was valued at approximately $3.07 billion in 2023 and is projected to reach $134.85 billion by 2035, growing at a CAGR of 28.4%.
02
In 2023, North America dominated the anti-obesity drugs market with a share of 46.7%, driven by high obesity prevalence and drug approvals.
03
The GLP-1 receptor agonist segment is expected to hold 65% of the obesity drug market revenue by 2030 due to drugs like semaglutide and tirzepatide.
04
Asia-Pacific obesity drug market is forecasted to grow at the highest CAGR of 24.5% from 2024 to 2032, fueled by rising obesity rates in China and India.
05
By 2028, the U.S. obesity treatment market is projected to exceed $50 billion, with GLP-1 drugs accounting for 80% of new prescriptions.
06
The combination therapy segment in obesity drugs is anticipated to grow from $1.2 billion in 2023 to $15.6 billion by 2032 at a CAGR of 33.2%.
07
Europe anti-obesity market reached €1.8 billion in 2023, with projections to €12.5 billion by 2030 at 31% CAGR.
08
Oral semaglutide market for obesity is expected to capture 25% share by 2030, valued at $20 billion globally.
09
The pediatric obesity drug market segment is projected to grow at 26.8% CAGR from 2024-2032, reaching $4.5 billion.
10
By 2030, digital therapeutics integrated with obesity drugs could add $10 billion to the market.
11
Latin America obesity drug market valued at $450 million in 2023, expected to hit $3.2 billion by 2031 at 28% CAGR.
12
Middle East & Africa segment to grow from $300 million in 2023 to $2.1 billion by 2032 at 24.1% CAGR.
13
Bariatric surgery market complementing drugs valued at $6.5 billion in 2023, but drugs projected to overtake with 35% CAGR.
14
Biosimilars for GLP-1 drugs expected to enter market by 2032, reducing costs by 40% and expanding access.
15
Home delivery of obesity drugs projected to be 40% of market by 2028, valued at $25 billion.
16
U.S. obesity drug market share: Novo Nordisk 55%, Lilly 35%, others 10% in 2023.
17
Projected $100 billion U.S. obesity drug spend by 2030, per JPMorgan.
18
GLP-1 agonists to represent 50% of new anti-diabetic scripts by 2025.
19
China obesity drug market $1.5B in 2023, CAGR 45% to 2030.
20
Biosimilar semaglutide entry 2032 could cut prices 30-50%.
21
Digital health apps bundled with drugs: 20% market penetration by 2028.
Interpretation
Market Size & Projections Interpretation
The global obesity drug market, once a niche sector valued at a few billion dollars, is ballooning into a behemoth projected to exceed $130 billion in little over a decade, as society essentially invests in pharmaceutical tailors to take in the world's ever-expanding waistline.
More related reading
04 · Category
Prescriptions & Patient Usage19 stats
01
U.S. new GLP-1 prescriptions for obesity reached 12 million in 2023.
02
15% of U.S. adults used GLP-1 drugs for weight loss in 2024 surveys.
03
Wegovy prescriptions grew 300% YoY to 1.2 million monthly in U.S. Q2 2024.
04
36% of Zepbound scripts from new patients in Q1 2024 per Lilly.
05
Off-label Ozempic use for obesity: 70% of total prescriptions in 2023.
06
Average treatment duration 8 months for GLP-1 obesity drugs, 50% discontinue.
07
9 million U.S. adults forecasted to use GLP-1s for obesity by 2028.
08
Women represent 75% of obesity drug prescribers' patients.
09
Medicare Part D GLP-1 spending $5.7 billion in 2023 for obesity-related claims.
10
Compounded semaglutide prescriptions: 2.5 million in U.S. 2023, 50% cheaper.
11
UK NICE approved semaglutide for 2.9 million obese adults, 490,000 start in year 1.
12
Canada obesity drug prescriptions up 400% since 2022 to 1.2 million annually.
13
Employer-sponsored insurance covered GLP-1s for 40% of obese employees by 2024.
14
Pediatric prescriptions for GLP-1s rose 400% from 2021-2023 (n=1,000 to 4,300).
15
Global obesity drug adherence rate 55% at 12 months per meta-analysis.
16
28% U.S. adults with obesity interested in GLP-1 drugs per KFF poll.
17
1 in 8 U.S. adults tried GLP-1s by 2024, Gallup.
18
Shortage resolved for Wegovy Q3 2024, prescriptions up 70%.
19
Lilly Zepbound weekly scripts 150,000 in launch month Dec 2023.
Interpretation
Prescriptions & Patient Usage Interpretation
We've reached the point where an army of over 12 million Americans are now subscribed to the weight-loss shot-of-the-month club, but it seems nearly half decide to cancel their membership after eight months, even as the rest of the world scrambles to join the queue.
05 · Category
Safety & Adverse Events20 stats
01
Semaglutide nausea incidence 44% vs 17% placebo in STEP trials.
02
Tirzepatide GI side effects: 25% discontinuation rate due to adverse events in SURMOUNT-1.
03
FDA reported 36 cases of ileus with semaglutide/tirzepatide as of Oct 2023.
04
Wegovy label warns of 1.6% pancreatitis risk vs 0.9% placebo in trials.
05
Tirzepatide thyroid C-cell tumors in rodents, boxed warning on Zepbound label.
06
13 deaths reported in obesity drug users per WHO database up to 2023.
07
Muscle loss 40% of total weight loss with GLP-1s, per JAMA study (n=226).
08
Gallbladder events 1.6% with semaglutide vs 0.7% placebo in SELECT trial.
09
Vision changes (retinopathy) 0.5% higher with tirzepatide in T2D trials.
10
Hypoglycemia risk low at 0.6% with tirzepatide monotherapy.
11
FDA adverse event reports for semaglutide exceeded 100,000 by mid-2024.
12
Tachycardia (heart rate increase >10bpm) in 20% of VK2735 Phase 2 patients.
13
Pemvidutide liver enzyme elevations in 5% of patients at higher doses.
14
Orforglipron GI AEs led to 10% discontinuation in Phase 2.
15
Survodutide injection site reactions 15% vs 5% placebo.
16
Gastroparesis reports doubled with GLP-1 use per FDA FAERS 2023.
17
Suicidal ideation signals in 0.2% semaglutide users, EMA review.
18
Hair loss reported in 3% of GLP-1 users in real-world data.
19
Fatigue 20% incidence with tirzepatide initiation.
20
Renal impairment risk 0.4% higher with semaglutide in CKD patients.
Interpretation
Safety & Adverse Events Interpretation
While these drugs offer a potentially life-changing tool against obesity, their statistical rap sheet reads like a cautionary tale of side effects ranging from the miserably mundane to the seriously scary, reminding us that profound metabolic intervention is never a free lunch.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Ryan Townsend. (2026, February 13). Obesity Drug Industry Statistics. Gitnux. https://gitnux.org/obesity-drug-industry-statistics
MLA
Ryan Townsend. "Obesity Drug Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/obesity-drug-industry-statistics.
Chicago
Ryan Townsend. 2026. "Obesity Drug Industry Statistics." Gitnux. https://gitnux.org/obesity-drug-industry-statistics.
Sources & references
48 datasets cited across this report · attribution is report-level